Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Corthera  Acquired by Novartis (2009 $ 620,000,000 )

1660 Amphlett Blvd. #200
San Mateo, CA 94402
USA
(650)-235-3555
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Thomas G. Wiggans (Connetics Former CEO/Chairman) Dennis Podlesak (Domain Associates Partner) Risa Stack (Kleiner Perkins Partner) Brian Dovey (Domain Associates General Partner) Lowell E. Sears (Sears Capital Management)
Company

Business description: Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera’s lead product candidate, relaxin, is currently being evaluated in clinical trials for the treatment of acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com. Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.
Partners include: University of Florida
Capital

Rounds: 4
Recent Fundings: Dec 2009   Dec 2007
Capital raised: 55.0M
Last Round: 1.6M
Ownership: Acquired by Novartis (2009 $ 620,000,000 )
VCs include: Domain AssociatesKleiner PerkinsJKandB CapitalSears Capital Management;  Quicksilver Ventures;  Caxton Advantage Life Sciences Fund
Angels/other VCs: Dennis M. Lanfear (Lanfear Capital Advisors)

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2009
Sector: Medical
Year Founded: 2002
Rounds: 4
Recent Fundings: Dec 2009   Dec 2007
Capital Raised: 55.0M
Last Round: 1.6M
Ownership: Acquired by Novartis (2009 $ 620,000,000 )